Serous Tubal Intraepithelial Carcinoma: a Concise Review for the Practicing Pathologist and Clinician

Total Page:16

File Type:pdf, Size:1020Kb

Serous Tubal Intraepithelial Carcinoma: a Concise Review for the Practicing Pathologist and Clinician diagnostics Review Serous Tubal Intraepithelial Carcinoma: A Concise Review for the Practicing Pathologist and Clinician S. Emily Bachert 1 , Anthony McDowell Jr. 2, Dava Piecoro 1 and Lauren Baldwin Branch 2,* 1 Department of Pathology and Laboratory Medicine, University of Kentucky College of Medicine, Lexington, KY 40536, USA; [email protected] (S.E.B.); [email protected] (D.P.) 2 Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Kentucky College of Medicine, Lexington, KY 40536, USA; [email protected] * Correspondence: [email protected] Received: 16 December 2019; Accepted: 8 February 2020; Published: 13 February 2020 Abstract: Ovarian cancer is the deadliest gynecologic malignancy, accounting for more than 14,000 deaths each year. With no established way to prevent or screen for it, the vast majority of cases are diagnosed as International Federation of Gynecology and Obstetrics (FIGO) stage III or higher. Individuals with germline BRCA mutations are at particularly high risk for epithelial ovarian cancer and have been the subject of many risk-reducing strategies. In the past ten years, studies looking at risk-reducing salpingo-oophorectomy (RRSO) in this population have uncovered an interesting association: up to 8% of women with BRCA1 or BRCA2 mutations who underwent RRSO had an associated serous tubal intraepithelial carcinoma (STIC). The importance of this finding is highlighted by the fact that up to 60% of ovarian cancer patients will also have an associated STIC. These studies have led to a paradigm shift that a subset of epithelial ovarian cancer originates not in the ovarian epithelium, but rather in the distal fallopian tube. In response to this, many providers have changed their practice by expanding the role of routine salpingectomy, hysterectomy, and sterilization procedures. The American College of Obstetricians and Gynecologists (ACOG) has acknowledged opportunistic salpingectomy as a safe strategy to reduce the risk of epithelial ovarian cancer in Committee Opinion #774. It is thus important for pathologists and clinicians to understand the definition of STIC; how it is diagnosed; and, most importantly, its clinical significance. Keywords: STIC; epithelial ovarian cancer; BRCA mutation 1. Background Information There are three broad categories of primary ovarian tumors: germ cell tumors, sex cord-stromal tumors, and surface/epithelial tumors. Surface epithelial tumors can be subclassified into five different cell types: Brenner, mucinous, clear cell, endometrioid, and serous. In each of these five cell types, tumors can range from benign to borderline (low-malignant potential) to malignant (carcinoma) [1]. Ovarian serous carcinomas can be further divided into low- and high-grade serous carcinomas (HGSOC), the latter being the focus of this review. Women in the United States have a lifetime risk of 1.38% for developing HGSCs, with a mean age of 63 years at presentation. HGSCs have a strong association with BRCA mutations and almost ubiquitously harbor TP53 mutations [2]. Unfortunately, HGSOCs carry a poor prognosis, representing over 70% of all epithelial ovarian cancer deaths [3]. Pathologists and clinicians can thus benefit from a better understanding of tumor pathogenesis. For a multitude of reasons to be discussed in this review, the current prevailing theory is that HGSOCs arise from STICs of the fallopian tube. Diagnostics 2020, 10, 102; doi:10.3390/diagnostics10020102 www.mdpi.com/journal/diagnostics Diagnostics 2020, 10, 102 2 of 8 Diagnostics 2020, 10, x FOR PEER REVIEW 2 of 8 2. Making the Pathologic Diagnosis 2. Making the Pathologic Diagnosis Microscopically, the epithelium of the fallopian tube consists of a mixture of secretory and ciliated Microscopically, the epithelium of the fallopian tube consists of a mixture of secretory and cells. The stroma underlying this epithelium is composed of smooth muscle and fibroconnective ciliated cells. The stroma underlying this epithelium is composed of smooth muscle and tissue, and the serosal surface is lined by mesothelium. Interestingly, there is regional variation fibroconnective tissue, and the serosal surface is lined by mesothelium. Interestingly, there is regional in the composition of the epithelial layer. Secretory cells predominate in the isthmus of the tube, variation in the composition of the epithelial layer. Secretory cells predominate in the isthmus of the and ciliated cells are most conspicuous at the fimbriated end [4]. A spectrum of entities originating tube, and ciliated cells are most conspicuous at the fimbriated end [4]. A spectrum of entities fromoriginating secretory from cells secretory have been cells described, have been including described, secretory including/stem secretory cell outgrowths/stem cell (SCOUTs),outgrowths p53 signatures,(SCOUTs), serous p53 signatures, tubal epithelial serous proliferationstubal epithelial or proliferations lesions of uncertain or lesions significance of uncertain (STEP-US), significance and serous(STEP tubal-US), and intraepithelial serous tubal carcinomas intraepithelial (STIC). carcinomas On this (STIC). spectrum On this of spectrum pathologies, of pathologies, STIC is the STIC most morphologicallyis the most morphologically atypical. It atypical. is characterized It is characterized as secretory as secretory cell lesions cell lesions with some with degreesome degree of cellular of depolarizationcellular depolarization (typically, (typically, but not always, but not with always, epithelial with epithelial stratification), stratification), increased increased nuclear to nuclear cytoplasmic to ratios,cytoplasmic hyperchromasia, ratios, hyperchrom nuclearasia, molding, nuclear prominent molding, nucleoli,prominent and nucleoli, increased and mitoticincreased activity mitotic [5 ,6] (Figureactivity1). [5,6 In] addition(Figure 1). to In these addition morphologic to these morphologic criteria, TP53 criteria,mutations TP53 mutations are present are present in 92% in of 92% STICs. Theof lesionsSTICs. The therefore lesions typicallytherefore demonstratetypically demonstrate strong and strong diff useand p53diffuse immunohistochemical p53 immunohistochemical staining consistentstaining consistent with missense with mutationsmissense mutations (Figure1B). (Figure Less commonly,1B). Less commonly, there is complete there is complete absence ofabsence staining dueof tostaining nonsense due mutationsto nonsense in mutationsTP53 [2]. in TP53 [2]. A B C FigureFigure 1. 1.( A(A)) Serous Serous tubaltubal intraepithelialintraepithelial carcinoma (STIC (STIC)) (left) (left) versus versus uninvolved uninvolved fallopian fallopian tube tube (right).(right). The The STIC STIC demonstrates demonstrates lossloss of polarity with with an an increase increase in in nuclear nuclear size size with with nuclear nuclear crowding crowding andand molding. molding. ( B(B)) p53 p53 immunohistochemistryimmunohistochemistry highlighting highlighting strong strong and and diffuse diffuse expression expression in STIC in STIC (left) (left) versusversus uninvolved uninvolved fallopian fallopian tubetube (right).(right). ( C)) Lower Lower magnification magnification highlighting highlighting the the hyperchromasia hyperchromasia andand marked marked nuclear nuclear pleomorphism pleomorphism associatedassociated with with STIC. STIC. AsAs morphologic morphologic findings findings may may sometimes sometimes bebe subtle,subtle, interpretationsinterpretations are unavoidably subjective. subjective. It isIt thus is thus not unexpectednot unexpect thated that there there is poor is poor reproducibility reproducibility in diagnosingin diagnosing these these precursor precursor lesions. lesions. At At least twoleast studies two studies have confirmed have confirmed this low this interobserver low interobserver agreement. agreement. First, First, Carslon Carslon et al. et circulated al. circulated digital imagesdigital of images 30 cases of (1430 cases (14 of STICcases and of STIC 16 cases and with 16 cases benign with tubal benign epithelium) tubal epithelium) to 12 pathologists. to 12 Thepathologists. majority agreed The majority on STIC agreed in only on nineSTIC ofin 14only cases, nine resulting of 14 cases, in aresultingκ statistic in ofa κ 0.333 statistic [7]. of A 0.333 second study[7]. byA second Visvanathan study et by al. Visvanathan highlighted thatet al. even highlighted intraobserver that variabilityeven intra forobserver diagnosing variability STIC versusfor non-STICdiagnosing was STIC lackluster versus basednon-STIC on morphologicwas lackluster findings based on alone morphologic (κ ranged findings from 0.41 alone to (κ 0.68 ranged for five pathologists)from 0.41 to [ 60.68]. As for such, five pathologists) Vang et al. validated [6]. As such, an algorithm Vang et al. using validated an on-line an algorithm training setusing of H&Ean on and- immunohistochemicalline training set of H&E stained and slides immunohistochemical (p53 and Ki-67) originally stained developedslides (p53 by andVisvanathan Ki-67) originally et al. [6 ,8]. developed by Visvanathan et al. [6,8]. In these studies, foci morphologically suspicious for STIC In these studies, foci morphologically suspicious for STIC needed to show a Ki-67 labeling index needed to show a Ki-67 labeling index >10% and a mutant p53 staining pattern to be diagnosed as >10% and a mutant p53 staining pattern to be diagnosed as such. The group was able to increase such. The group was able to increase the interobserver κ value for STIC vs. non-STIC
Recommended publications
  • Diagnostic Immunochemistry in Gynaecological Neoplasia Guide to Diagnosis
    International Journal of Scientific and Research Publications, Volume 9, Issue 9, September 2019 356 ISSN 2250-3153 Diagnostic Immunochemistry in Gynaecological Neoplasia Guide to Diagnosis S.S Pattnaik, J.Parija,S.K Giri, L.Sarangi, Niranjan Rout, S. Samantray, N. Panda,B.L Nayak, J.J Mohapatra, M.R Mohapatra, A.K Padhy Presently Working As Senior Resident In Dept Of Gynaecology Oncology, At Ahrcc ,M.B.B.S , M.D (O&G) DOI: 10.29322/IJSRP.9.09.2019.p9346 http://dx.doi.org/10.29322/IJSRP.9.09.2019.p9346 Abstract- AIM AND OBJECTIVE - This short review provides an updated overview of the essential immunochemical markers currently used in the diagnostics of gynaecological malignancies along with their molecular rationale. The new molecular markers has revolutionized the field of IHC MATERIAL METHODS -We have reviewed the recent ihc markers according to literature revision and our experiencewe, have discussed the the use of ihc , CONCLUSION- The above facts will help reach at a diagnosis in morphologically equivocal cases of gynaecology oncology pathology, and guide us to use a specific the panel of ihc ,which will help us reach accurate diagnosis. I. INTRODUCTION HC combines microscopic morphology with accurate molecular identification and allows in situ visualisation of specific protein I antigen . IHC has definite role in guiding cancer therapy.The role of pathologist is increasing beside tissue diagnoses , to perfoming IHC biomarker analyse ,assisting the development of novel markers. Ihc markers are being in used in new perspective , in guiding anticancer therapy.ihc represents a solid adjunct for the classification of gynaecological malignancies that improves intraobserver reproducibility and has potential of revealing unexpected features(1) OVARIAN IHC: • PAX -8 is the most specific marker, emerging to diagnose primary ovarian cancer,but it lacks sensibility as it is also expressed in metastasis from endocervix ,kidney and thyroid.
    [Show full text]
  • About Ovarian Cancer Overview and Types
    cancer.org | 1.800.227.2345 About Ovarian Cancer Overview and Types If you have been diagnosed with ovarian cancer or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Is Ovarian Cancer? Research and Statistics See the latest estimates for new cases of ovarian cancer and deaths in the US and what research is currently being done. ● Key Statistics for Ovarian Cancer ● What's New in Ovarian Cancer Research? What Is Ovarian Cancer? Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer and can spread. To learn more about how cancers start and spread, see What Is Cancer?1 Ovarian cancers were previously believed to begin only in the ovaries, but recent evidence suggests that many ovarian cancers may actually start in the cells in the far (distal) end of the fallopian tubes. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 What are the ovaries? Ovaries are reproductive glands found only in females (women). The ovaries produce eggs (ova) for reproduction. The eggs travel from the ovaries through the fallopian tubes into the uterus where the fertilized egg settles in and develops into a fetus. The ovaries are also the main source of the female hormones estrogen and progesterone. One ovary is on each side of the uterus. The ovaries are mainly made up of 3 kinds of cells. Each type of cell can develop into a different type of tumor: ● Epithelial tumors start from the cells that cover the outer surface of the ovary.
    [Show full text]
  • Primary Peritoneal Serous Papillary Carcinoma: a Case Series
    Archives of Gynecology and Obstetrics (2019) 300:1023–1028 https://doi.org/10.1007/s00404-019-05280-z GYNECOLOGIC ONCOLOGY Primary peritoneal serous papillary carcinoma: a case series Nikolaos Blontzos1 · Evangelos Vafas1 · George Vorgias1 · Nikolaos Kalinoglou1 · Christos Iavazzo1 Received: 27 May 2018 / Accepted: 22 August 2019 / Published online: 5 September 2019 © Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Purpose To present the clinical and laboratory characteristics, as well as the management, of patients with primary peritoneal serous papillary carcinoma (PPSPC). Methods This is a retrospective study of 19 patients with PPSPC who underwent debulking surgery followed by frst line chemotherapy and were managed in Metaxa Memorial Cancer Hospital between January 2002 and December 2017. Results The median age of the patients was found to be 66 years (range 44–76 years). Clinical presentation of PPSPC included abdominal distention and pain, constipation, as well as loss of appetite and weight gain. Two of the patients did not mention any symptomatology and the disease was suspected by an abnormal cervical smear and elevated CA125 levels respectively. Biomarkers measurement during the initial management of the patients revealed abnormal values of CA125 for all the participants (median value 565 U/ml). Human epididymis secretory protein 4 (HE4) and ratios of blood count were also measured. Perioperative Peritoneal Cancer Index ranged from 6 to 20. Optimal debulking was achieved in 5 cases. All patients were staged as IIIC and IVA PPSPC and received standard chemotherapy with paclitaxel and carboplatin, whereas bevacizumab was added in the 5 most recent cases. Median overall survival was 29 months.
    [Show full text]
  • Capecitabine)
    Reference number(s) 1993-A SPECIALTY GUIDELINE MANAGEMENT XELODA (capecitabine) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy. A. FDA-Approved Indications 1. Colorectal Cancer a. Xeloda is indicated as a single agent for adjuvant treatment in patients with Dukes’ C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. b. Xeloda is indicated as first-line treatment in patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. 2. Breast Cancer a. Xeloda in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. b. Xeloda monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated, for example, patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents. B. Compendial Uses 1. Anal cancer 2. Breast cancer 3. Central nervous system (CNS) metastases from breast cancer 4. Colorectal Cancer 5. Esophageal and esophagogastric junction cancer 6. Gastric cancer 7. Head and neck cancer 8. Hepatobiliary cancers (extra-/intra-hepatic cholangiocarcinoma and gallbladder cancer) 9. Occult primary tumors (cancer of unknown primary) 10. Ovarian cancer (Epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer/mucinous cancer) 11.
    [Show full text]
  • Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations
    International Journal of Molecular Sciences Review Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations Isao Otsuka Kameda Medical Center, Department of Obstetrics and Gynecology, Kamogawa 296-8602, Japan; [email protected] Abstract: Ovarian high-grade serous carcinomas (HGSCs) are a heterogeneous group of diseases. They include fallopian-tube-epithelium (FTE)-derived and ovarian-surface-epithelium (OSE)-derived tumors. The risk/protective factors suggest that the etiology of HGSCs is multifactorial. Inflammation caused by ovulation and retrograde bleeding may play a major role. HGSCs are among the most genetically altered cancers, and TP53 mutations are ubiquitous. Key driving events other than TP53 mutations include homologous recombination (HR) deficiency, such as BRCA 1/2 dysfunction, and activation of the CCNE1 pathway. HR deficiency and the CCNE1 amplification appear to be mutually exclusive. Intratumor heterogeneity resulting from genomic instability can be observed at the early stage of tumorigenesis. In this review, I discuss current carcinogenic hypotheses, sites of origin, etiologic factors, and molecular alterations of HGSCs. Keywords: ovarian cancer; high-grade serous carcinoma; carcinogenesis; molecular alterations Citation: Otsuka, I. Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic 1. Introduction Factors, and Molecular Alterations. Ovarian cancer is the most lethal gynecological malignancy. Epithelial ovarian cancers Int. J. Mol. Sci. 2021, 22, 4409. (EOCs) are a heterogeneous group of diseases and can be divided into five main types, https://doi.org/10.3390/ijms based on histopathology and molecular genetics [1]: high-grade serous, low-grade serous, 22094409 endometrioid, clear cell, and mucinous tumors.
    [Show full text]
  • Histopathology of Gynaecological Cancers
    1 Histopathology of gynaecological cancers Ovarian tumours Ovarian tumours are classified based on cell types, Classification of Tumours of the Ovary patterns of growth and, whenever possible, on Epithelial tumours (ET) histogenesis (WHO Classification 2014). Sex cord–stromal tumours (SCST) There are 3 major categories of primary ovarian tumour: Germ cell tumours (GCT) epithelial tumours (ETs), sex cord–stromal tumours Monodermal teratoma and somatic type tumours arising from dermoid cyst (SCSTs) and germ cell tumours (GCTs). Secondary Germ cell–sex cord stromal tumours tumours are not infrequent. Mesenchymal and mixed epithelial and mesenchymal tumours The incidence of malignant forms varies with age. Other rare tumours, tumour-like conditions Carcinomas, accounting for over 80%, peak at the 6th Lymphoid and myeloid tumours decade; SCSTs peak in the perimenopausal period; GCTs Secondary tumours peak in the first three decades. Prognosis is worse for WHO, 2014 carcinomas. Stage I: Tumour confined to ovaries or Fallopian tube(s) IA: Tumour limited to 1 ovary (capsule intact) or Fallopian tube; no tumour on ovarian or Fallopian tube surface; no malignant cells in the ascites or peritoneal The staging classification has been recently revised washings (FIGO 2013 Classification) and ovarian, Fallopian tube IB: Tumour limited to both ovaries (capsules intact) or Fallopian tubes; no and peritoneal cancer are classified together. tumour on ovarian or Fallopian tube surface; no malignant cells in the ascites or peritoneal washings Stage I cancer is confined to the ovaries or Fallopian IC: Tumour limited to 1 or both ovaries or Fallopian tubes, with any of the following: • IC1: Surgical spill tubes.
    [Show full text]
  • Prognostic Factors for Patients with Early-Stage Uterine Serous Carcinoma Without Adjuvant Therapy
    J Gynecol Oncol. 2018 May;29(3):e34 https://doi.org/10.3802/jgo.2018.29.e34 pISSN 2005-0380·eISSN 2005-0399 Original Article Prognostic factors for patients with early-stage uterine serous carcinoma without adjuvant therapy Keisei Tate ,1 Hiroshi Yoshida ,2 Mitsuya Ishikawa ,1 Takashi Uehara ,1 Shun-ichi Ikeda ,1 Nobuyoshi Hiraoka ,2 Tomoyasu Kato 1 1Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan 2Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan Received: Nov 29, 2017 ABSTRACT Revised: Jan 15, 2018 Accepted: Jan 26, 2018 Objective: Uterine serous carcinoma (USC) is an aggressive type 2 endometrial cancer. Data Correspondence to on prognostic factors for patients with early-stage USC without adjuvant therapy are limited. Keisei Tate This study aims to assess the baseline recurrence risk of early-stage USC patients without Department of Gynecology, National Cancer adjuvant treatment and to identify prognostic factors and patients who need adjuvant therapy. Center Hospital, 5 Chome-1-1 Tsukiji, Chuo-ku, Methods: Sixty-eight patients with International Federation of Gynecology and Obstetrics Tokyo 104-0045, Japan. (FIGO) stage I–II USC between 1997 and 2016 were included. All the cases did not undergo E-mail: [email protected] adjuvant treatment as institutional practice. Clinicopathological features, recurrence Copyright © 2018. Asian Society of patterns, and survival outcomes were analyzed to determine prognostic factors. Gynecologic Oncology, Korean Society of Results: FIGO stages IA, IB, and II were observed in 42, 7, and 19 cases, respectively. Median Gynecologic Oncology follow-up time was 60 months. Five-year disease-free survival (DFS) and overall survival This is an Open Access article distributed under the terms of the Creative Commons (OS) rates for all cases were 73.9% and 78.0%, respectively.
    [Show full text]
  • Mixed Epithelial Carcinoma of the Endometrium: Recommendations for Diagnosis from the Isgyp Endometrial Carcinoma Project
    Mixed Epithelial Carcinoma of the Endometrium: Recommendations for Diagnosis from the ISGyP Endometrial Carcinoma Project Joseph Rabban MD MPH Pathology Department University of California San Francisco March 2017 Introduction The 2014 edition of the World Health Organization (WHO) Classification of Tumors of the Female Reproductive Organs recognizes mixed carcinoma (also called mixed cell adenocarcinoma by WHO) as a specific histologic category of epithelial endometrial cancer.(1) The 2014 WHO defines it as a tumor composed of “two or more different histological types of endometrial carcinoma, at least one of which is of the type II category.” The term “type II” category refers to non-endometrioid, non-mucinous types (e.g. serous carcinoma, clear cell carcinoma, carcinosarcoma). The rationale for recognizing this category stems largely from the adverse behavior of tumors that contain as little as 5% of a component of serous carcinoma admixed with endometrioid adenocarcinoma, with the implication that the type II tumor component should drive patient management. The International Society of Gynecologic Pathologists (ISGyP) Endometrial Carcinoma Project has reviewed this definition and identified areas that merit clarification and areas that remain controversial. This lecture will address practical recommendations for the diagnosis of mixed epithelial carcinoma of the endometrium and review the key entities in the differential diagnosis. Clinical Significance The literature on mixed epithelial carcinoma of the endometrium is composed of three kinds of studies: 1.) studies of endometrial serous carcinoma in which some of the cases are pure serous carcinoma and some are mixed with endometrioid adenocarcinoma; 2.) studies of endometrial clear cell carcinoma in which some cases are pure and some are mixed with other cancer types; 3.) studies specifically of mixed endometrial cancers.
    [Show full text]
  • XELODA (Capecitabine)
    Reference number(s) 1993-A SPECIALTY GUIDELINE MANAGEMENT XELODA (capecitabine) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy. A. FDA-Approved Indications 1. Colorectal Cancer a. Xeloda is indicated as a single agent for adjuvant treatment in patients with Dukes’ C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. b. Xeloda is indicated as first-line treatment in patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. 2. Breast Cancer a. Xeloda in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. b. Xeloda monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated, for example, patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents. B. Compendial Uses 1. Anal cancer 2. Breast cancer 3. Central nervous system (CNS) metastases from breast cancer 4. Colorectal Cancer 5. Esophageal and esophagogastric junction cancer 6. Gastric cancer 7. Head and neck cancers (including very advanced head and neck cancer) 8. Hepatobiliary cancers (including extrahepatic and intra-hepatic cholangiocarcinoma and gallbladder cancer) 9. Occult primary tumors (cancer of unknown primary) 10. Ovarian cancer, fallopian tube cancer, and primary peritoneal cancer: Epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and mucinous cancer) 11.
    [Show full text]
  • Ovarian Cancer: the New Paradigm (And What You Need to Know Clinically)
    Ovarian Cancer: The New Paradigm (and what you need to know clinically) Dianne Miller, M.D., FRCSC University of British Columbia and the British Columbia Cancer Agency Ovarian Cancer y Germ Cell: y Stromal tumors y Dysgerminoma y Lymphoma y Endodermal sinus y Sarcoma etc. y Teratoma etc. y Epithelial Tumors y Sex cord stromal y Serous y Granulosa cell y Mucinous y FOX L2 y Endometriod y Sertoli leydig etc y Clear cell etc. Objectives y To discuss why epithelial ovarian cancer is becoming vanishingly rare! y To discuss our new insights into ovarian cancer y Epithelial Ovarian Cancer is a least five distinct diseases y High Grade Serous* y Endometriod* y Clear cell* y Mucinous y Low Grade Serous y (and possibly transitional cell) y To discuss the clinical implications of the changes in our understanding of the origin of “Ovarian Cancers” “Ovarian” Cancer in Canada y modest lifetime risk of 1/70, but: y major public health issue: y 2500 new cases/annum: 1750 deaths y potential years of life lost from cancer: y breast 94,400 = 1.0 y ovary 28,600 0.3 y uterus 11,400 y cervix 10,100 International Benchmarking y The Lancet, Volume 377, Issue 9760, Pages 127 ‐ 138, 8 January 2011 y Published Online: 22 December 2010 y Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995—2007 (the International Cancer Benchmarking Partnership): an analysis of population‐based cancer registry data “Ovarian Cancer” y Screening ineffective y Survival rates low & stable “Ovarian Cancer” Presentation y 1/3 gradual intrapelvic growth → y lower
    [Show full text]
  • A New Potential Serum Biomarker for Uterine Serous Papillary Cancer
    Imaging, Diagnosis, Prognosis HumanKallikrein6:ANewPotentialSerumBiomarkerforUterine Serous Papillary Cancer Alessandro D. Santin,1Eleftherios P.Diamandis,2 Stefania Bellone,1Antoninus Soosaipillai,2 Stefania Cane,1 Michela Palmieri,1Alexander Burnett,1Juan J. Roman,1 and Sergio Pecorelli3 Abstract Purpose:The discovery of novel biomarkers might greatly contribute to improve clinical manage- ment and outcomes in uterine serous papillary carcinoma (USPC), a highly aggressive variant of endometrial cancer. Experimental Design: Human kallikrein 6 (hK6) gene expression levels were evaluated in 29 snap-frozen endometrial biopsies, including13 USPC, 13 endometrioid carcinomas, and 3 normal endometrial cells by real-time PCR. Secretion of hK6 protein by 14 tumor cultures, including3 USPC, 3 endometrioid carcinoma, 5 ovarian serous papillary carcinoma, and 3 cervical cancers, was measured usinga sensitive ELISA. Finally, hK6 concentration in 79 serum and plasma sam- ples from 22 healthy women, 20 women with benign diseases, 20 women with endometrioid car- cinoma, and17USPC patients was studied. Results: hK6 gene expression levels were significantly higher in USPC when compared with endometrioid carcinoma (mean copy number by real-time PCR, 1,927 versus 239, USPC versus endometrioid carcinoma; P < 0.01). In vitro hK6 secretion was detected in all primary USPC cell lines tested (mean, 11.5 Ag/L) and the secretion levels were similar to those found in primary ovarian serous papillary carcinoma cultures (mean, 9.6 Ag/L). In contrast, no hK6 secretion was detectable in primary endometrioid carcinoma and cervical cancer cultures. hK6 serum and plasma concentrations (mean F SE) amongnormal healthy females (2.7 F 0.2 Ag/L), patients with benign diseases (2.4 F 0.2 Ag/L), and patients with endometrioid carcinoma (2.6 F 0.2 Ag/L) were not significantly different.
    [Show full text]
  • Specialty Guideline Management
    Reference number(s) 2040-A SPECIALTY GUIDELINE MANAGEMENT GEMZAR (gemcitabine) gemcitabine POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy. A. FDA-Approved Indications 1. Ovarian cancer In combination with carboplatin for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy 2. Breast cancer In combination with paclitaxel for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated 3. Non-small cell lung cancer In combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer (NSCLC) 4. Pancreatic cancer As first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemzar or gemcitabine is indicated for patients previously treated with fluorouracil. B. Compendial Uses 1. Bladder cancer, primary carcinoma of the urethra, upper genitourinary tract tumors, transitional cell carcinoma of the urinary tract, urothelial carcinoma of the prostate, non-urothelial and urothelial cancer with variant histology 2. Bone cancer a. Ewing’s sarcoma b. Osteosarcoma 3. Breast cancer 4. Head and neck cancers (including very advanced head and neck cancer and cancer of the nasopharynx) 5. Hepatobiliary and biliary tract cancer a. Extrahepatic cholangiocarcinoma b. Intrahepatic cholangiocarcinoma c.
    [Show full text]